Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis (PHOMS)

This is an interventional treatment trial for Multiple Sclerosis focused on measuring Extracorporeal Photopheresis, Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Read More

Inclusion Criteria:

1. Demonstrate Expanded Disability Status Scale (EDSS) scores between 3 to 6.5 at screening.

2. Documented EDSS progression in the 2 years prior to screening of 1 point or greater for patients with an EDSS score less than 6 at baseline, and greater than or equal to 0.5 for patients with an EDSS score greater than or equal to 6.0 at baseline *.

   * If documented EDSS scores are not available, a written summary of the clinical evidence of disability progression over the last 2 years, and retrospective assessment of EDSS score from data in the medical records, must be submitted for review by the principal investigators.

3. Documented initial onset characterized by a relapsing-remitting course as described in the Diagnostic Criteria.
4. Age ≥ 18 ≤ 75 years.
5. Weight > 40 kg.
6. Hematocrit ≥ 28 % (with or without transfusion support).
7. Platelet count > 100,000 per μL (with or without transfusion support).
8. Willingness to use at least 1 reliable method of birth control (e.g., abstinence, oral contraceptives, intrauterine devices, barrier method with spermicide, or surgical sterilization) throughout the study for all men and women of childbearing potential.
9. Willingness to participate in all PHOMS Study tests, visits, and procedures (including the ECP), as outlined in the informed consent.
10. Patients must have adequate peripheral venous access to initiate ECP therapy, and central line insertion shall be required.
11. The patient agrees to participate in the trial and signs the PHOMS Study informed consent form.

Exclusion Criteria:

1. Absolute medical contraindication to receive ECP.

2. Laboratory evidence of any of the following:

   • White blood cells (WBC) < 2,000 cells per uL.
   • Serum transaminase levels > x 2 UNL.
   • Creatinine Clearance < 60 mL/min.
3. Concurrent diagnosis of a neurological condition that would interfere with the assessment of MS, or an autoimmune disease or inflammatory condition that is chronically treated with immunosuppressive agents.
4. Evidence of known infection with human immunodeficiency virus (HIV) or active (not including latent) Hepatitis B.
5. Uncontrolled infection requiring treatment at study entry.
6. Hypersensitivity or allergy to psoralen (methoxalen).
7. Hypersensitivity or allergy to both heparin and citrate products (If hypersensitive or allergic to only one of these products, exclusion does not apply).
8. Inability to tolerate fluid changes associated with ECP (e.g., inadequate renal, hepatic, pulmonary and cardiac function leading to enable patient to tolerate extracorporeal volume shifts associated with ECP).
9. Presence of aphakia or photosensitive disease (systemic lupus erythematosus, porphyrias, etc.).
10. Women who are pregnant and/or lactating.
11. Use of any investigational drug/treatment at the time of enrollment or within the previous 60 days, or five elimination half-lives, or until the expected pharmodynamic effect has returned to baseline, whichever is longer.

12. Treatment with any of the medications or procedures listed below:

    • Natalizumab, or rituximab within 3 months prior to randomization.
    • Cyclophosphamide within 1 year prior to randomization.
    • Mitoxantrone, ofatumumab, ocrelizumab, cladribine, or daclizumab within 1 years prior to randomization.
    • Intravenous immunoglobulin within 3 months prior to randomization.
    • Plasmapheresis within 3 months prior to randomization.
13. Inability to undergo MRI scans.
14. Contraindication to gadolinium due to past allergic, hypersensitive, or adverse reaction or impaired renal function. Patients receiving a steroid prep prior to gadolinium administration due to history of hypersensitivity or allergy to other agents or due to prior mild reaction to gadolinium will not be excluded from the study.
15. Poor venous access.
16. Previous history of skin cancer, leukemia / lymphoma / myeloma, or bone marrow transplant.
17. Patients taking Coumadin who are unable to switch from oral anticoagulants to enoxaparin.
18. Heparin-induced thrombocytopenia.
19. Poor cardiac function.
20. Severe hypotension.
21. Any other disease or condition which, in the opinion of the investigator, could interfere with participation according to the PHOMS Study Protocol, or with the ability of the patients to cooperate and comply with study procedures.
22. Inability to provide informed consent.